Patents for monitoring medical devices has been approved in Singapore, Mexico and Japan
Brighter’s AI patent for a system to monitor and predict wear and tear of a medical device has been approved in Singapore and Mexico. In Japan, Brighter’s patent for using a mobile device for monitoring a medical device has been approved.
“For patient-safety reasons, it is of great importance that mobile medical equipment works properly and is reliable. At the same time such devices, usually carried around by the users at all times, are likely to be exposed to a number of external stress factors such as temperature changes, humidity or chock if the user drops the device, which can cause damage. Furthermore, daily use causes general wear. It’s important for us to be able to monitor this remotely, optimally through advanced AI technology, so that we can quickly identify a potential problem and repair or replace the product in case the user hasn't noticed and reported it,” says Henrik Norström, CEO.
For further information, please contact:
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, firstname.lastname@example.org, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
The Annual General Meeting of Nanoform Finland Plc (“Nanoform”) has on 7 April 2020 authorized the company’s Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Limited Liability Compa...
Meddelande om stabiliseringsåtgärder
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, JAPAN, NYA ZEELAND, SINGAPORE, SYDAFRIKA, HONGKONG, SCHWEIZ ELLER ANNAT LAND TILL JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING SKULLE VARA OLAGLIG, OTIL...
BioStock: Chordate Medical's CEO comments on the terminated study
Chordate Medical has for a longer period of time conducted two parallel studies – one in rhinitis (chronic nasal congestion) and one in chronic migraine – with the company’s technology Kinetic Oscillation Stimulation. Chordate Medical has now chosen to suspend recruitment for the rhinitis study as a...
Hanna Myhrman utses till Chefsjurist och medlem i ADDvise Groups koncernledning - Regulatoriskt meddelande
Om ADDvise Group ADDvise Group AB (publ) är en ledande leverantör av utrustning till sjukvårds- och forskningsenheter. Koncernen består av ett 10-tal dotterbolag organiserade i två affärsområden, Lab och Sjukvård. Försäljning sker globalt. Koncernen har en tydlig förvärvsstrategi med syfte att höja...